This Team is Built to Find this Mechanism of Action

Nehal Mehta

Nehal N. Mehta, MD, MSCE, FAHA

 

Adjunct Associate Professor of Medicine, attending cardiologist, and Director, Inflammatory Risk, Preventive Cardiology, Hospital of the University of Pennsylvania. Adjunct Scholar, Center for Clinical Biostatistics and Epidemiology, University of Pennsylvania School of Medicine. Inaugural Lasker Clinical Scholar and former tenured Senior Investigator, NIH.

At NIH, he was principal investigator in the Vascular Inflammation in Psoriasis Trial, a randomized controlled trial of NB-UVB and biologics for psoriasis.

Nehal is a healthcare innovator with 20+ years of academic clinical care and translational research experience. He is an experienced principal investigator of clinical trials in humans testing impact of novel therapies.

Hector DeLuca

Professor Hector DeLuca

 

U.Wisconsin & WARF, The godfather of vitamin D synthesis and expert in MS & UVB preclinical research. Twice nominated for the Nobel Prize.

PureHart

Professor Prue Hart

 

Department of Inflammation, Telethon Institute for Child Health Research, UWA. PI of PhoCIS Trial. Nominated for the Burnet Medal and Oration, Australasian Society for Immunology, 2021.

Prof. Dr. med. univ. Peter Wolf

 

MD, PhD Chair of Dermatology and Director of the Research Unit of Photo-dermatology, and Full Professor for Dermatology and Bio-immunotherapy at the Medical University of Graz, Austria. His clinical and research interests focus on photo-dermatology and photo-immunology.

Alina G. Bridges

 

DO Director of Immuno-dermatology at Ritchfield laboratory. 20 years at the Mayo Clinic as Medical and Hospital Dermatologist and Immuno-dermatologist.

Richard Weller

 

Senior lecturer in Dermatology at the University of Edinburgh. Leading researcher in population health & UVB impact on cardiovascular & hypertension research.

Carmen Castilla

 

MD Medical Dermatologist at New York Dermatology Group. Dr. Castilla sees the skin’s critical interplay with the systemic immune system as an important and non-invasive pathway to systemic immunomodulation.

Chris Emig

 

PhD  CEO of Augmenta BioWorks. discovers new therapeutics by harnessing natural human immunity. Augmenta is 4 for 4 in targeted discovery to date including a partnership with TFF Therapeutics.